Us Astrazeneca Trial
- All
- News
- Videos
-
Vaccine Trial Patient In US Sues AstraZeneca, Claiming She Was Left "Permanently Disabled"
An American woman who claims she was "permanently disabled" after taking part in the US clinical trial of AstraZeneca's COVID-19 vaccine is suing the drug maker because they failed to provide her with medical care for her side effects.
-
AstraZeneca COVID-19 Vaccine 76% Effective In Updated US Trial Results
AstraZeneca said on Thursday its COVID-19 vaccine was 76% effective at preventing symptomatic illness, citing a new analysis of up-to-date results for its major US trial.
-
As Pandemic Worsens, Why AstraZeneca Vaccine Is In Spotlight
AstraZeneca has said it is standing by its coronavirus vaccine after a US agency raised concerns about trial results that showed the shot to be highly effective in preventing Covid-19.
-
AstraZeneca To Release More Data On US Covid Jab Trials "Within 48 Hours"
UK-based pharmaceutical giant AstraZeneca said Tuesday it will release further data "within 48 hours" on US trials of its Covid-19 vaccine, after health officials raised concerns about the initial information disclosed.
-
AstraZeneca May Have Included Outdated Trial Data: US Agency
A United States health agency raised concerns Tuesday that AstraZeneca may have included out-of-date information during trials of its Covid-19 vaccine, the day after the company said its drug was highly effective in preventing the disease.
-
AstraZeneca's US Trial Shows COVID-19 Vaccine 79 Per Cent Effective
Pharmaceutical giant AstraZeneca said Monday that trials showed its Covid-19 vaccine is 100 percent effective in preventing severe disease, as a row simmered between Britain and the EU over much-needed supplies of the jab.
-
AstraZeneca Vaccine Found 79% Effective In US Trials
AstraZeneca's COVID-19 vaccine performed better than expected in a major late-stage trial potentially paving the way for its emergency authorization in the United States and bolstering confidence in the shot after numerous setbacks in Europe.
-
Oxford Vaccine Shot That Works Better In Smaller Doses Raises Questions
The news reached Sarah Gilbert Saturday evening that the Covid-19 vaccine she's developed with AstraZeneca Plc appeared to work. But the University of Oxford professor had expected a key number: Was it more than 90% effective, as others have been -- or less?
-
AstraZeneca, Johnson & Johnson Covid Vaccine Trials Back On Track In US
Two major clinical trials for experimental Covid-19 vaccines got back on track in the United States Friday -- providing a glimmer of hope as the number of cases skyrocket across the country.
-
AstraZeneca COVID-19 Vaccine Trial In US On Hold Until Midweek: Report
AstraZeneca's COVID-19 vaccine trial remains on hold in the United States pending a U.S. investigation into a serious side effect in Britain even as other trials of the vaccine resume, sources familiar with the details told Reuters.
-
AstraZeneca, Ranbaxy Prevail in Nexium Antitrust Trial
The verdict, handed down Friday in federal court in Boston, is the first time a jury has decided such a case since the US Supreme Court ruled last year that so-called "pay-for-delay" settlements may run afoul of antitrust laws.
-
Vaccine Trial Patient In US Sues AstraZeneca, Claiming She Was Left "Permanently Disabled"
An American woman who claims she was "permanently disabled" after taking part in the US clinical trial of AstraZeneca's COVID-19 vaccine is suing the drug maker because they failed to provide her with medical care for her side effects.
-
AstraZeneca COVID-19 Vaccine 76% Effective In Updated US Trial Results
AstraZeneca said on Thursday its COVID-19 vaccine was 76% effective at preventing symptomatic illness, citing a new analysis of up-to-date results for its major US trial.
-
As Pandemic Worsens, Why AstraZeneca Vaccine Is In Spotlight
AstraZeneca has said it is standing by its coronavirus vaccine after a US agency raised concerns about trial results that showed the shot to be highly effective in preventing Covid-19.
-
AstraZeneca To Release More Data On US Covid Jab Trials "Within 48 Hours"
UK-based pharmaceutical giant AstraZeneca said Tuesday it will release further data "within 48 hours" on US trials of its Covid-19 vaccine, after health officials raised concerns about the initial information disclosed.
-
AstraZeneca May Have Included Outdated Trial Data: US Agency
A United States health agency raised concerns Tuesday that AstraZeneca may have included out-of-date information during trials of its Covid-19 vaccine, the day after the company said its drug was highly effective in preventing the disease.
-
AstraZeneca's US Trial Shows COVID-19 Vaccine 79 Per Cent Effective
Pharmaceutical giant AstraZeneca said Monday that trials showed its Covid-19 vaccine is 100 percent effective in preventing severe disease, as a row simmered between Britain and the EU over much-needed supplies of the jab.
-
AstraZeneca Vaccine Found 79% Effective In US Trials
AstraZeneca's COVID-19 vaccine performed better than expected in a major late-stage trial potentially paving the way for its emergency authorization in the United States and bolstering confidence in the shot after numerous setbacks in Europe.
-
Oxford Vaccine Shot That Works Better In Smaller Doses Raises Questions
The news reached Sarah Gilbert Saturday evening that the Covid-19 vaccine she's developed with AstraZeneca Plc appeared to work. But the University of Oxford professor had expected a key number: Was it more than 90% effective, as others have been -- or less?
-
AstraZeneca, Johnson & Johnson Covid Vaccine Trials Back On Track In US
Two major clinical trials for experimental Covid-19 vaccines got back on track in the United States Friday -- providing a glimmer of hope as the number of cases skyrocket across the country.
-
AstraZeneca COVID-19 Vaccine Trial In US On Hold Until Midweek: Report
AstraZeneca's COVID-19 vaccine trial remains on hold in the United States pending a U.S. investigation into a serious side effect in Britain even as other trials of the vaccine resume, sources familiar with the details told Reuters.
-
AstraZeneca, Ranbaxy Prevail in Nexium Antitrust Trial
The verdict, handed down Friday in federal court in Boston, is the first time a jury has decided such a case since the US Supreme Court ruled last year that so-called "pay-for-delay" settlements may run afoul of antitrust laws.
